Albuminuria and CKD: Tackling the silent marker with SGLT2 inhibitors

views
Streamed on 20 Mar, 2025, 11:00 AM

ABOUT THIS SESSION

Chronic kidney disease (CKD) is often a silent but progressive condition, with albuminuria serving as a key marker of kidney damage and cardiovascular risk. Recent advances in nephrology have highlighted the crucial role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in slowing CKD progression and reducing albuminuria.

FACULTY
Dr. Rohit Khandelwal
Dr. Rohit Khandelwal
Consultant Nephrologist at Navjeevan Hospital, Gwalior

Latest Archived Videos

More from Nephrologist

Logo

Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks